Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib
More precise criteria for TACE unsuitability are required. The combination of mALBI grade and the N3-S5-S10 criteria may better identify patients with intermediate-stage HCC who are unlikely to benefit from TACE. Validation in a larger cohort is warranted.
Authors
- Winnie Yeo (ORCID: https://orcid.org/0000-0002-0863-8469)
- Edwin P. Hui (ORCID: https://orcid.org/0000-0002-8134-7019)
- Leung Li (ORCID: https://orcid.org/0000-0002-0251-0253)
- Simon C.H. Yu (ORCID: https://orcid.org/0000-0002-8715-5026)
- Stephen L. Chan (ORCID: https://orcid.org/0000-0001-8998-5480)
- LM Chen
Institutions
- Chinese University of Hong Kong (HK)
Publication Details
- Journal
- Hong Kong Medical Journal
- Published
- 2025-12-05
- DOI
- https://doi.org/10.12809/hkmj2311239
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00